Study on Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors

Sponsor: Merck Sharp & Dohme LLC

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT06395103

Provider View

This clinical trial is testing the safety and effectiveness of a new drug, zilovertamab vedotin, in children and young adults with certain types of blood cancers and solid tumors that have not responded to previous treatments.

Patient Parameters

Program Overview

This study is part of a larger research project and focuses on evaluating how well the drug zilovertamab vedotin works and how safe it is for children with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, or neuroblastoma. It also includes young adults with Ewing sarcoma.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with specific blood cancers like B-precursor B-ALL or DLBCL/Burkitt lymphoma.
  • Diagnosed with solid tumors such as neuroblastoma or Ewing sarcoma.

Exclusion Criteria

  • History of organ transplant.
  • Serious heart disease.
  • Liver cirrhosis.
  • Severe nerve damage.
  • Certain genetic nerve disorders.
  • Down syndrome.
  • Ongoing graft-versus-host disease or treatment for it.
  • HIV infection.
  • Allergic to any part of the study drug.
  • Recent radiation therapy within 4 weeks before starting the study.
  • Long-term steroid use above a certain dose.
  • Use of certain medications that affect liver enzymes within a specific time before the study.
  • Recent cancer treatments or experimental drugs within 4 weeks before the study.
  • Recent live vaccines within 30 days before the study.
  • Other active cancers needing treatment in the past year.
  • Active infections needing treatment.
  • Hepatitis B or C infection.
  • Not fully recovered from major surgery.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.